These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32143981)

  • 1. Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging.
    Lietzau G; Magni G; Kehr J; Yoshitake T; Candeias E; Duarte AI; Pettersson H; Skogsberg J; Abbracchio MP; Klein T; Nyström T; Ceruti S; Darsalia V; Patrone C
    Neurobiol Aging; 2020 May; 89():12-23. PubMed ID: 32143981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type 2 diabetes impairs odour detection, olfactory memory and olfactory neuroplasticity; effects partly reversed by the DPP-4 inhibitor Linagliptin.
    Lietzau G; Davidsson W; Östenson CG; Chiazza F; Nathanson D; Pintana H; Skogsberg J; Klein T; Nyström T; Darsalia V; Patrone C
    Acta Neuropathol Commun; 2018 Feb; 6(1):14. PubMed ID: 29471869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice.
    Darsalia V; Olverling A; Larsson M; Mansouri S; Nathanson D; Nyström T; Klein T; Sjöholm Å; Patrone C
    Regul Pept; 2014 May; 190-191():25-31. PubMed ID: 24821550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DPP-4 Inhibitor and Sulfonylurea Differentially Reverse Type 2 Diabetes-Induced Blood-Brain Barrier Leakage and Normalize Capillary Pericyte Coverage.
    Elabi OF; Karampatsi D; Vercalsteren E; Lietzau G; Nyström T; Klein T; Darsalia V; Patrone C; Paul G
    Diabetes; 2023 Mar; 72(3):405-414. PubMed ID: 36448982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of Glycemia in the Recovery Phase After Stroke Counteracts the Detrimental Effect of Obesity-Induced Type 2 Diabetes on Neurological Recovery.
    Augestad IL; Pintana H; Larsson M; Krizhanovskii C; Nyström T; Klein T; Darsalia V; Patrone C
    Diabetes; 2020 Sep; 69(9):1961-1973. PubMed ID: 32540876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DPP-4 inhibition with linagliptin ameliorates the progression of premature aging in klotho-/- mice.
    Hasegawa Y; Hayashi K; Takemoto Y; Cheng C; Takane K; Lin B; Komohara Y; Kim-Mitsuyama S
    Cardiovasc Diabetol; 2017 Dec; 16(1):154. PubMed ID: 29195509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
    BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic Heterogeneity and Risk of Severe Hypoglycemia with Concomitant Use of Sulfonylureas and DPP-4 Inhibitors: Population-Based Cohort Study.
    Dimakos J; Cui Y; Platt RW; Renoux C; Filion KB; Douros A
    Clin Pharmacol Ther; 2023 Sep; 114(3):712-720. PubMed ID: 37326010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase-4 Inhibition: A Hypothesis-Generating Analysis from the MARLINA-T2D Trial.
    Siwy J; Klein T; Rosler M; von Eynatten M
    Proteomics Clin Appl; 2019 Mar; 13(2):e1800144. PubMed ID: 30632692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice.
    Ma M; Hasegawa Y; Koibuchi N; Toyama K; Uekawa K; Nakagawa T; Lin B; Kim-Mitsuyama S
    Cardiovasc Diabetol; 2015 May; 14():54. PubMed ID: 25986579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute and Chronic Exposure to Linagliptin, a Selective Inhibitor of Dipeptidyl Peptidase-4 (DPP-4), Has an Effect on Dopamine, Serotonin and Noradrenaline Level in the Striatum and Hippocampus of Rats.
    Łupina M; Wąsik A; Baranowska-Bosiacka I; Tarnowski M; Słowik T; Listos P; Kotlińska J; Kosik-Bogacka D; Gutowska I; Listos J
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment.
    Rizzo MR; Barbieri M; Boccardi V; Angellotti E; Marfella R; Paolisso G
    J Gerontol A Biol Sci Med Sci; 2014 Sep; 69(9):1122-31. PubMed ID: 24671867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice.
    Aroor AR; Habibi J; Kandikattu HK; Garro-Kacher M; Barron B; Chen D; Hayden MR; Whaley-Connell A; Bender SB; Klein T; Padilla J; Sowers JR; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2017 May; 16(1):61. PubMed ID: 28476142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
    Penno G; Garofolo M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis.
    Liao X; Song L; Zeng B; Liu B; Qiu Y; Qu H; Zheng Y; Long M; Zhou H; Wang Y; Du Y; Xu J; Shen R; Tong Q; Cai L; Li X; Guo S; Yang G; Zhu Z; Pu X; Wei H; Zheng H
    EBioMedicine; 2019 Jun; 44():665-674. PubMed ID: 30922964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes.
    Fadini GP; Bonora BM; Albiero M; Zaninotto M; Plebani M; Avogaro A
    Cardiovasc Diabetol; 2017 Feb; 16(1):22. PubMed ID: 28183314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway.
    Chiazza F; Tammen H; Pintana H; Lietzau G; Collino M; Nyström T; Klein T; Darsalia V; Patrone C
    Cardiovasc Diabetol; 2018 May; 17(1):60. PubMed ID: 29776406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nigrostriatal dopamine system of aging GFRalpha-1 heterozygous mice: neurochemistry, morphology and behavior.
    Zaman V; Boger HA; Granholm AC; Rohrer B; Moore A; Buhusi M; Gerhardt GA; Hoffer BJ; Middaugh LD
    Eur J Neurosci; 2008 Oct; 28(8):1557-68. PubMed ID: 18973577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans.
    Batchu SN; Yerra VG; Liu Y; Advani SL; Klein T; Advani A
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32796688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.